{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:41:07Z","timestamp":1787236867700,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Patients with inflammatory bowel disease (IBD) face an increased risk of developing intestinal and extraintestinal cancers. This retrospective single-center study aimed to quantify cancer risk and identify potential risk factors associated with cancer in IBD patients. Methods: The epidemiological data, disease characteristics, treatment regimens, and occurrences of cancer following IBD diagnosis were collected between January 2021 and February 2022. Hazard ratios (HRs) and standardized incidence ratios (SIRs) were estimated. Results: 560 IBD patients were included; 37 patients developed cancer, with 5 patients developing two distinct cancers, resulting in 42 cancers overall. This translated into a twofold increased risk of developing any cancer compared to the general population (SIR 1.94, 95% CI 1.4\u20132.6). Colorectal (CRC, 29%), skin (19%), and breast cancer (17%) were the most common malignancies. Female patients showed an increased risk for all cancers (SIR 3.1, 95% CI 2.06\u20134.3), melanoma (SIR 5.6, 95% CI 1.14\u201316.2), and CRC (SIR 7.5, 95% CI 3\u201315.4). Conversely, male patients exhibited a significantly increased risk of lymphoma (SIR 26.2, 95% CI 3.2\u201395.7). Young age at IBD diagnosis and the use of immunomodulators, whether as monotherapy or in combination with biologics, were associated with an increased risk of cancer. Conclusions: The risk of CRC and lymphoma in IBD patients may be higher than previously reported, potentially due to the increasing use of combination therapy. Cancer risk in IBD should be regularly assessed and personalized throughout the disease course.<\/jats:p>","DOI":"10.3390\/cancers17091396","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T20:11:48Z","timestamp":1745352708000},"page":"1396","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk Factors for Intestinal and Extraintestinal Cancers in Inflammatory Bowel Disease: A Retrospective Single-Center Cohort Study"],"prefix":"10.3390","volume":"17","author":[{"given":"Rosa","family":"Rosania","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Nord","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian G.","family":"Scurt","sequence":"additional","affiliation":[{"name":"University Clinic for Nephrology and Hypertension, Diabetology and Endocrinology, Otto-von-Guericke University, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Lux","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Medical Informatics, Otto-von-Guericke University, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Keitel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"von Arnim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-0974","authenticated-orcid":false,"given":"Marino","family":"Venerito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.3748\/wjg.v12.i30.4807","article-title":"Etiopathogenesis of inflammatory bowel diseases","volume":"12","author":"Danese","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","article-title":"Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years","volume":"143","author":"Jess","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/gutjnl-2011-301133","article-title":"Inflammatory bowel disease therapies and cancer risk: Where are we and where are we going?","volume":"61","author":"Beaugerie","year":"2012","journal-title":"Gut"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1097\/MIB.0000000000000540","article-title":"Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis","volume":"21","author":"Packey","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.3748\/wjg.v23.i33.6137","article-title":"Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases","volume":"23","author":"Halling","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_14","first-page":"1770","article-title":"Risk of malignancy in patients with inflammatory bowel disease: A population-based cohort study from China","volume":"150","author":"Zhang","year":"2022","journal-title":"Int. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.cgh.2023.04.001","article-title":"Increasing Risk of Lymphoma Over Time in Crohn\u2019s Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study","volume":"21","author":"Smedby","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/j.gastro.2012.04.054","article-title":"Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010","volume":"143","author":"Herrinton","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S-212","DOI":"10.1016\/S0016-5085(23)01469-5","article-title":"961. Temporal Trends and relative risks of intestinal and extraintestinal cancers in persons with inflammatory bowel disease: A population-based study from a large Canadian province","volume":"164","author":"Murthy","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/ajg.2013.249","article-title":"Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: A Danish population-based cohort study","volume":"108","author":"Jess","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Laredo, V., Garc\u00eda-Mateo, S., Mart\u00ednez-Dom\u00ednguez, S., La L\u00f3pez de Cruz, J., Gargallo-Puyuelo, C.J., and Gomoll\u00f3n, F. (2023). Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. Cancers, 15.","DOI":"10.3390\/cancers15030871"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"(2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1396\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:19:35Z","timestamp":1760030375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091396"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091396","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}